Specifically targeting ERK1 or ERK2 kills Melanoma cells

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Qin, Jianzhong ^a   Xin, Hong ^b   Nickoloff, Brian J ^c,d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

BRAF; Drug resistance; ERK; Melanoma; PLX4032

Indexed keywords

B RAF KINASE; BIM PROTEIN; CASPASE 3; CASPASE 8; MITOGEN ACTIVATED PROTEIN KINASE 1; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN BAD; PROTEIN BAK; SHORT HAIRPIN RNA; VEMURAFENIB; AGAR; BENZAMIDE DERIVATIVE; CASPASE; DIPHENYLAMINE; DRUG DERIVATIVE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEINASE INHIBITOR; SMALL INTERFERING RNA; SULFONAMIDE; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PHOSPHORYLATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; NUCLEOTIDE SEQUENCE; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL DEATH; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; MELANOMA; METABOLISM; MITOCHONDRION; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

AGAR; BCL-2-ASSOCIATED X PROTEIN; BENZAMIDES; CASPASES; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DIPHENYLAMINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; INDOLES; MELANOMA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM PROTEINS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEASE INHIBITORS; RNA, SMALL INTERFERING; SULFONAMIDES; TUMOR STEM CELL ASSAY;

EID: 84856088091     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-15     Document Type: Article

References (45)

1. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol 2009, 129:1666-1674. 10.1038/jid.2008.423, 2866180, 19131946.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
4. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 2003, 4:95-98. 10.1016/S1535-6108(03)00189-2, 12957284.
5. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867. 10.1016/S0092-8674(04)00215-6, 15035987.
6. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov 2011, 10:811-812. 10.1038/nrd3579, 22037033.
7. Ji Z, Flaherty KT, Tsao H. Targeting the RAS pathway in melanoma. Trends Mol Med 2012, 18:27-35. 10.1016/j.molmed.2011.08.001, 21962474.
8. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599. 10.1038/nature09454, 2948082, 20823850.
9. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819. 10.1056/NEJMoa1002011, 20818844.
10. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435. 10.1038/nature08833, 20130576.
11. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972. 10.1038/nature09627, 3058384, 21107320.
12. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010, 107:14903-14908. 10.1073/pnas.1008990107, 2930420, 20668238.
13. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977. 10.1038/nature09626, 3143360, 21107323.
14. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430. 10.1038/nature08902, 3178447, 20179705.
15. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009, 106:4519-4524. 10.1073/pnas.0900780106, 2649208, 19251651.
16. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int J Cancer 2003, 104:527-532. 10.1002/ijc.10978, 12594806.
17. Cooper JA, Hunter T. Major substrate for growth factor-activated protein-tyrosine kinases is a low-abundance protein. Mol Cell Biol 1985, 5:3304-3309. 369150, 3879813.
18. Kohno M. Diverse mitogenic agents induce rapid phosphorylation of a common set of cellular proteins at tyrosine in quiescent mammalian cells. J Biol Chem 1985, 260:1771-1779.
19. Rossomando AJ, Payne DM, Weber MJ, Sturgill TW. Evidence that pp 42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase. Proc Natl Acad Sci USA 1989, 86:6940-6943. 10.1073/pnas.86.18.6940, 297966, 2550926.
20. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH, Yancopoulos GD. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991, 65:663-675. 10.1016/0092-8674(91)90098-J, 2032290.
21. Pages G, Guerin S, Grall D, Bonino F, Smith A, Anjuere F, Auberger P, Pouyssegur J. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999, 286:1374-1377. 10.1126/science.286.5443.1374, 10558995.
22. Yao Y, Li W, Wu J, Germann UA, Su MS, Kuida K, Boucher DM. Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation. Proc Natl Acad Sci USA 2003, 100:12759-12764. 10.1073/pnas.2134254100, 240691, 14566055.
23. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006, 46:249-279. 10.1016/j.advenzreg.2006.01.004, 16854453.
24. Madhunapantula SV, Robertson GP. Is B-Raf a good therapeutic target for melanoma and other malignancies?. Cancer Res 2008, 68:5-8. 10.1158/0008-5472.CAN-07-2038, 18172288.
25. Sturgill TW. MAP kinase: it's been longer than fifteen minutes. Biochem Biophys Res Commun 2008, 371:1-4. 10.1016/j.bbrc.2008.04.002, 18406346.
26. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD, Thompson JF, Bron LP, Hersey P. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 2005, 58:1163-1169. 10.1136/jcp.2005.025957, 1770768, 16254105.
27. Lejeune FJ, Rimoldi D, Speiser D. New approaches in metastatic melanoma: biological and molecular targeted therapies. Expert Rev Anticancer Ther 2007, 7:701-713. 10.1586/14737140.7.5.701, 17492933.
28. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011, 364:772-774. 10.1056/NEJMcibr1013704, 21345109.
29. Jayaraman S. Flow cytometric determination of mitochondrial membrane potential changes during apoptosis of T lymphocytic and pancreatic beta cell lines: comparison of tetramethylrhodamineethylester (TMRE), chloromethyl-X-rosamine (H2-CMX-Ros) and MitoTracker Red 580 (MTR580). J Immunol Methods 2005, 306:68-79. 10.1016/j.jim.2005.07.024, 16256133.
30. Qin JZ, Xin H, Sitailo LA, Denning MF, Nickoloff BJ. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res 2006, 66:9636-9645. 10.1158/0008-5472.CAN-06-0747, 17018621.
31. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005, 65:6282-6293. 10.1158/0008-5472.CAN-05-0676, 16024630.
32. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev 2007, 17:31-39. 10.1016/j.gde.2006.12.005, 17208430.
33. Sheridan C, Brumatti G, Elgendy M, Brunet M, Martin SJ. An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. Oncogene 2010, 29:6428-6441. 10.1038/onc.2010.380, 20802529.
34. Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010, 102:1724-1730. 10.1038/sj.bjc.6605714, 2883709, 20531415.
35. Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama A, Saida T, Takata M. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer 2011, 104:464-468. 10.1038/sj.bjc.6606072, 3049568, 21224857.
36. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008, 68:6145-6153. 10.1158/0008-5472.CAN-08-1430, 18676837.
37. Ferrell JE. Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. Curr Opin Cell Biol 2002, 14:140-148. 10.1016/S0955-0674(02)00314-9, 11891111.
38. Mansour SJ, Resing KA, Candi JM, Hermann AS, Gloor JW, Herskind KR, Wartmann M, Davis RJ, Ahn NG. Mitogen-activated protein (MAP) kinase phosphorylation of MAP kinase kinase: determination of phosphorylation sites by mass spectrometry and site-directed mutagenesis. J Biochem 1994, 116:304-314.
39. Bermudez O, Pages G, Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol 299:C189-202.
40. Brummer T, Naegele H, Reth M, Misawa Y. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene 2003, 22:8823-8834. 10.1038/sj.onc.1207185, 14654779.
41. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, Morrison DK. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005, 17:215-224. 10.1016/j.molcel.2004.11.055, 15664191.
42. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009, 16:368-377. 10.1038/cdd.2008.148, 18846109.
43. Puzanov I, Burnett P, Flaherty KT. Biological challenges of BRAF inhibitor therapy. Mol Oncol 2011, 5:116-123. 10.1016/j.molonc.2011.01.005, 21393075.
44. Nissan MH, Solit DB. The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?. Curr Oncol Rep 2011, 13:479-487. 10.1007/s11912-011-0198-4, 21997758.
45. Retsas S. Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?. J R Soc Med 2011, 104:269-272. 10.1258/jrsm.2011.100405, 21659402.